~~<i id='22020AFDBA'><strike id='22020AFDBA'><tt id='22020AFDBA'><pre id='22020AFDBA'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-09-30 08:56:08 Page View：832

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Doctors push to include dialysis machines in emergency stockpile

ArielBrigham,whowasunabletoaccessdialysisduringHurricaneHarveyin2017,posesforaportraitinherhome.Mich

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Doctors push to include dialysis machines in emergency stockpile

ArielBrigham,whowasunabletoaccessdialysisduringHurricaneHarveyin2017,posesforaportraitinherhome.Mich